Arthritis news and arthritis widget

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, today announced positive data from its ICH compliant Phase II equivalent multi-center study of MRX-4 (n=105) in patients suffering from allergic rhinitis. MRX-4 was given as an intranasal spray formulation. The Nasal Allergen Challenge (NAC) study was conducted in allergic rhinitis patients outside of the local allergy season.

Did you get your flu shot yet for this season? We did -- in mid-October. Unlike other years, we were told the doctor's office had plenty of flu shots in...